Studies two blood pressure pills combined in one tablet for high blood pressure
Observes a combined pill of fimasartan and amlodipine in adults with high blood pressure.
Key facts
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- Status
- Recruiting
- People taking part
- 20,000 people, planned
- Started
- 23 Jun 2022
- Planned end
- Jun 2026
- Type of study
- Observational
- Record updated
- 12 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential hypertension (high blood pressure with no other known cause) who plan to take a fimasartan/amlodipine pill or a fimasartan/amlodipine/hydrochlorothiazide pill.
- Age
- 19 years or older
- Sex
- Men and women can join.
- Disease stage
- Essential hypertension. One group has severe hypertension (stage 2 or higher, sitting SBP ≥ 160 mmHg or sitting DBP ≥ 100 mmHg) or high-risk hypertension and has never taken blood pressure drugs.
- Earlier treatment
- Some can join if they already take fimasartan/amlodipine with hydrochlorothiazide, or a fimasartan/hydrochlorothiazide combination with amlodipine. Others can join if blood pressure is still sitting SBP ≥ 140 mmHg or sitting DBP ≥ 90 mmHg despite blood pressure drugs.
Main reasons for not taking part
- Suspected or confirmed secondary hypertension
- Cannot take fimasartan combinations according to the drug label
- Currently in another drug or device trial, or took a trial drug within 12 weeks
- Judged by the investigators as not fit for this study
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- Inclusion Criteria:; Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on; Males and females over the age of 19; Patients who have been diagnosed with essential hypertension and plan to be treated with fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide; If the patient is applicable, one of the following; If the patients have severe hypertension, stage 2 or higher(sit SBP ≥ 160 mmHg or sit DBP ≥ 100 mmHg), or high-risk hypertension (The cardiovascular risk score of the 2018 hypertension treatment guidelines by the Korean Society of Hypertension is applied.) The patients have never been treated with antihypertensive drugs for essential hypertension; If the patients are on concomitant administration of fimasartan/amlodipin and hydrochlorothiazide for essential hypertension or, If the patients are on concomitant administration of a fimasartan/hydrochlorothiazide combination and amlodipine for essential hypertension; If the patients have a blood pressure of sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg even though they have been treated with antihypertensive drugs for essential hypertension; The patients who understand this study and are available to participate in this study until the end of the study period with a cooperative attitude
- Exclusion Criteria:; The patients who are suspected of having secondary hypertension or confirmed to have secondary hypertension; The patients who are contraindicated to taking fimasartan complex according to the drug labelling; The patients who are currently participation in another clinical trials (Drugs or medical devices) The patients who took an investigational drug within 12 weeks of the enrollment date; However, the following patients can participate in this study:; The patients who are currently enrolled in non-interventional clinical studies or who are being followed up on after the administration of investigational drugs has ended; The patients who are not suitable for this study by the investigators
Where in South Korea
- Seoul National University Bundang HospitalSeoul, South KoreaContact: InHo Chae, M.D., Ph.D.Taking people
About the trial
What the trial wants to find out
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide, based on fimasartan. (Stage 1).
Read full original descriptionShow less
Also, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Prospective, Observational Study to Evaluate Effectiveness and Safety of Fixed-dose Combinations of Fimasartan/Amlodipine or Fimasartan/Amlodipine/Hydrochlorothiazide in Essential Hypertensive Patients
- Plain-language title
- Studies two blood pressure pills combined in one tablet for high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 September 2025